Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union

Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacology and therapeutics 2023-05, Vol.113 (5), p.960-962
Hauptverfasser: Sakurai, Akira, Kanzaki, Seiichi, Honda, Futaba
Format: Artikel
Sprache:eng
Schlagworte:
Drug Industry - legislation & jurisprudence
European Union
Japan
Pharmaceutical Preparations
Pharmacy
United States
Viruses
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 962
container_issue 5
container_start_page 960
container_title Clinical pharmacology and therapeutics
container_volume 113
creator Sakurai, Akira
Kanzaki, Seiichi
Honda, Futaba
description
doi_str_mv 10.1002/cpt.2788
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2738492066</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2738492066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3558-6ff26049660143521b72296bf69a333ce38d11e359d9b505fefadf88eb6489083</originalsourceid><addsrcrecordid>eNp1kNFKHDEUhkOp1NUKfQLJZW9GM8kkm1yWZW0Vi2J39XLIzJy4kZlkmmQo-xR95WZXq1dCIOT8Xz44P0JfSnJWEkLP2zGd0bmUH9Cs5IwWgjP-Ec0IIapQlIlDdBTjU35WSspP6JCJilT5zNDfKz1qBxHw7UaHQbcwJdvqHt_B49TrZL2L2Bu8dI_WAQTo8L0NOb-HNvkQsfEB_4Ru_2edNQs_jHqHPdi0wauNzzPrcNoAXjubcvAr6QQRa9ftp8sp-BG028XefUYHRvcRTl7uY7S-WK4WP4rrm--Xi2_XRcs4l4Uwhoq8jRCkrBinZTOnVInGCKUZYy0w2ZUlMK461XDCDRjdGSmhEZVURLJj9PXZOwb_e4KY6sHGFvo-l-GnWNM5k5WiRIg3tA0-xgCmHoMddNjWJal39de5_npXf0ZPX6xTM0D3Cv7vOwPFM_DH9rB9V1Qvbld74T8neo8P</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2738492066</pqid></control><display><type>article</type><title>Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Sakurai, Akira ; Kanzaki, Seiichi ; Honda, Futaba</creator><creatorcontrib>Sakurai, Akira ; Kanzaki, Seiichi ; Honda, Futaba</creatorcontrib><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.2788</identifier><identifier>PMID: 36404404</identifier><language>eng</language><publisher>United States</publisher><subject>Drug Industry - legislation &amp; jurisprudence ; European Union ; Japan ; Pharmaceutical Preparations ; Pharmacy ; United States ; Viruses</subject><ispartof>Clinical pharmacology and therapeutics, 2023-05, Vol.113 (5), p.960-962</ispartof><rights>2022 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3558-6ff26049660143521b72296bf69a333ce38d11e359d9b505fefadf88eb6489083</citedby><cites>FETCH-LOGICAL-c3558-6ff26049660143521b72296bf69a333ce38d11e359d9b505fefadf88eb6489083</cites><orcidid>0000-0001-8251-1098</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.2788$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.2788$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36404404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sakurai, Akira</creatorcontrib><creatorcontrib>Kanzaki, Seiichi</creatorcontrib><creatorcontrib>Honda, Futaba</creatorcontrib><title>Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><subject>Drug Industry - legislation &amp; jurisprudence</subject><subject>European Union</subject><subject>Japan</subject><subject>Pharmaceutical Preparations</subject><subject>Pharmacy</subject><subject>United States</subject><subject>Viruses</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kNFKHDEUhkOp1NUKfQLJZW9GM8kkm1yWZW0Vi2J39XLIzJy4kZlkmmQo-xR95WZXq1dCIOT8Xz44P0JfSnJWEkLP2zGd0bmUH9Cs5IwWgjP-Ec0IIapQlIlDdBTjU35WSspP6JCJilT5zNDfKz1qBxHw7UaHQbcwJdvqHt_B49TrZL2L2Bu8dI_WAQTo8L0NOb-HNvkQsfEB_4Ru_2edNQs_jHqHPdi0wauNzzPrcNoAXjubcvAr6QQRa9ftp8sp-BG028XefUYHRvcRTl7uY7S-WK4WP4rrm--Xi2_XRcs4l4Uwhoq8jRCkrBinZTOnVInGCKUZYy0w2ZUlMK461XDCDRjdGSmhEZVURLJj9PXZOwb_e4KY6sHGFvo-l-GnWNM5k5WiRIg3tA0-xgCmHoMddNjWJal39de5_npXf0ZPX6xTM0D3Cv7vOwPFM_DH9rB9V1Qvbld74T8neo8P</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Sakurai, Akira</creator><creator>Kanzaki, Seiichi</creator><creator>Honda, Futaba</creator><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8251-1098</orcidid></search><sort><creationdate>202305</creationdate><title>Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union</title><author>Sakurai, Akira ; Kanzaki, Seiichi ; Honda, Futaba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3558-6ff26049660143521b72296bf69a333ce38d11e359d9b505fefadf88eb6489083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Drug Industry - legislation &amp; jurisprudence</topic><topic>European Union</topic><topic>Japan</topic><topic>Pharmaceutical Preparations</topic><topic>Pharmacy</topic><topic>United States</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sakurai, Akira</creatorcontrib><creatorcontrib>Kanzaki, Seiichi</creatorcontrib><creatorcontrib>Honda, Futaba</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sakurai, Akira</au><au>Kanzaki, Seiichi</au><au>Honda, Futaba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2023-05</date><risdate>2023</risdate><volume>113</volume><issue>5</issue><spage>960</spage><epage>962</epage><pages>960-962</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><cop>United States</cop><pmid>36404404</pmid><doi>10.1002/cpt.2788</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-8251-1098</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2023-05, Vol.113 (5), p.960-962
issn 0009-9236
1532-6535
language eng
recordid cdi_proquest_miscellaneous_2738492066
source MEDLINE; Access via Wiley Online Library
subjects Drug Industry - legislation & jurisprudence
European Union
Japan
Pharmaceutical Preparations
Pharmacy
United States
Viruses
title Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T11%3A14%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Japanese%20Pharmaceutical%20Regulations%20of%20Engineered%20Viral%20Vectors%20for%20Medical%20Use%20Compared%20With%20Those%20in%20the%20United%20States%20and%20the%20European%20Union&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Sakurai,%20Akira&rft.date=2023-05&rft.volume=113&rft.issue=5&rft.spage=960&rft.epage=962&rft.pages=960-962&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.2788&rft_dat=%3Cproquest_cross%3E2738492066%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2738492066&rft_id=info:pmid/36404404&rfr_iscdi=true